SEC Form S-8 filed by OnKure Therapeutics Inc.
As filed with the Securities and Exchange Commission on March 10, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ONKURE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
47-2309515 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
6707 Winchester Circle, Suite 400 |
(Address of Principal Executive Offices, including zip code) |
OnKure Therapeutics, Inc. 2024 Equity Incentive Plan
OnKure Therapeutics, Inc. 2024 Employee Stock Purchase Plan
(Full title of the plan)
Nicholas A. Saccomano
President and Chief Executive Officer
6707 Winchester Circle, Suite 400
Boulder, CO 80301
(720) 307-2892
(Name, address and telephone number, including area code, of agent for service)
Copies to:
Tony Jeffries
Jennifer Knapp
Phillip McGill
Wilson Sonsini Goodrich & Rosati, P.C.
1155 Canyon Blvd., Suite 400
Boulder, CO 80302
(303) 256-5900
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|||
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|||
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 (the “Registration Statement”) is filed by OnKure Therapeutics, Inc. (the “Registrant”) for the purpose of registering (i) 667,355 additional shares of Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) of the Registrant reserved for issuance under the 2024 Equity Incentive Plan (the “2024 Plan”), pursuant to the provision of the 2024 Plan providing for an automatic increase in the number of shares reserved for issuance under the 2024 Plan, and (ii) 133,471 additional shares of Class A Common Stock of the Registrant reserved for issuance under the 2024 Employee Stock Purchase Plan (the “2024 ESPP”), pursuant to the provision of the 2024 ESPP providing for an automatic increase in the number of shares reserved for issuance under the 2024 ESPP.
PART II
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The Registrant previously registered shares of its Class A Common Stock for issuance under the 2024 Plan and the 2024 ESPP on a Registration Statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission on December 9, 2024 (File No. 333-283693) (the “Previous Form S-8”). Accordingly, pursuant to General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of the Previous Form S-8, including the information incorporated by reference therein and the periodic reports filed after the Previous Form S-8 to maintain current information about the Registrant, except as set forth below.
The following documents filed by the Registrant with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this Registration Statement:
All other reports or documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents; provided, however, that reports, documents and information, or portions thereof, deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement
contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.
EXHIBIT INDEX
Exhibit |
Exhibit Description |
Incorporated by Reference |
|||
Form |
File No. |
Exhibit |
Filing Date |
||
4.1 |
Amended and Restated Certificate of Incorporation, as amended, of OnKure Therapeutics, Inc. |
8-K |
001-40315 |
3.2 |
October 8, 2024 |
4.2 |
8-K |
001-40315 |
3.3 |
October 8, 2024 |
|
4.3 |
2024 Equity Incentive Plan and forms of agreement thereunder. |
8-K |
001-40315 |
10.14 |
October 8, 2024 |
4.4 |
8-K |
001-40315 |
10.15 |
October 8, 2024 |
|
5.1 |
|
|
|
|
|
23.1 |
Consent of KPMG LLP, independent registered public accounting firm. |
|
|
|
|
23.2 |
Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto). |
|
|
|
|
24.1 |
|
|
|
|
|
107 |
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on March 10, 2025.
ONKURE THERAPEUTICS, INC. |
||
|
|
|
By: |
|
/s/ Nicholas A. Saccomano |
|
|
Nicholas A. Saccomano |
|
|
President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Nicholas A. Saccomano and Jason Leverone, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Signature |
|
Title |
|
Date |
|
|
|
||
/s/ Nicholas A. Saccomano Nicholas A. Saccomano |
|
Chief Executive Officer, President and Director (Principal Executive Officer) |
|
March 10, 2025 |
|
|
|
||
/s/ Jason Leverone Jason Leverone |
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
|
March 10, 2025 |
|
|
|
||
/s/ R. Michael Carruthers R. Michael Carruthers |
|
Director |
|
March 10, 2025 |
|
|
|
||
/s/ Michael Grey Michael Grey |
|
Director |
|
March 10, 2025 |
|
|
|
||
/s/ Valerie M. Jansen Valerie M. Jansen |
|
Director |
|
March 10, 2025 |
|
|
|
||
/s/ Isaac Manke Isaac Manke |
|
Director |
|
March 10, 2025 |
|
|
|
||
/s/ Edward T. Mathers |
|
Director |
|
March 10, 2025 |
Edward T. Mathers |
|
|
|
|
|
|
|
||
/s/ Andrew Phillips |
|
Chairman |
|
March 10, 2025 |
Andrew Phillips |
|
|
|
|